Concepedia

Publication | Open Access

A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors

DOIFull Paper Access

41

Citations

21

References

2013

Year

Joseph P. Connor, Mihaela Cristea, Nancy Lewis, Lionel D. Lewis, Philip Komarnitsky, M.R. Mattiacci, Mildred Felder, Sarah Stewart, Josephine Harter, Jean Henslee-Downey,
BMC Cancer

Abstract

The combination of huKS-IL2 with low-dose cyclophosphamide was well tolerated. Although no objective responses were observed, the combination showed evidence of immunologic activity and 3 patients showed stable disease for ≥ 4 cycles.

References

YearCitations

Page 1